secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2026-10-29T11:06:28+00:00
Accession:  0000105770-26-000118
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

West Pharma Q3 net sales $874.5M, +8.7% YoY; raises FY26 sales and adjusted EPS guidance
--------------------------------------------------------------------------------

- Q3 net sales $874.5M, up 8.7% YoY (organic +11.9%); diluted EPS $3.02, up 57.3%; adjusted diluted EPS $2.66, up 35.7%.
- FY2026 net sales guidance raised to $3.41B-$3.42B from $3.345B-$3.380B; adjusted diluted EPS raised to $9.38-$9.48 from $8.85-$9.05.
- HVP Components net sales $466.7M, up 19.7% (organic +20.3%) and 53% of total; Proprietary Products segment sales $728.8M, up 12.6%.
- West Vantage net sales $145.7M, down 7.3% (organic -6.6%); Standard Products $163.0M, up 2.9%; SmartDose 3.5mL sales $11.8M vs $29.8M prior-year.
- Repurchased $231M stock in Q3, $685M YTD; YTD operating cash flow $403M; FY26 capex guidance cut to $215M-$220M; Q4 dividend $0.26/share, up 18%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/0000105770-26-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000118/wst-20261029.htm
  HTML page:      https://secwatch.observer/filing/0000105770-26-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer